Abstract 36P
Background
Our proteogenomic analysis using pancreatic ductal adenocarcinoma (PDAC) tissues provides significantly mutated genes/biomarkers, cell signaling pathways and cell types as potential therapeutic targets to improve stratification of PDAC patients (Nat. Can., 2023). The current study aimed to evaluate clinical chemotherapeutics to validate targeting molecules and signaling pathways based on previous results, using patient-derived primary cells and tumor organoids.
Methods
The sensitivity on drugs was also evaluated on established primary PDAC cells and tumor organoids. To explore the mechanistic molecular changes for the development of drug resistance, we established resistant-cells on gemcitabine combined with radiation through long term treatment of the combination and selection procedure. Signaling pathways, EMT and cancer were explored at protein as well as RNA levels, and metabolomics were performed
Results
PDAC cells and organoids showed growth inhibition when treated with inhibitors against RhoA phosphorylation, HIF1A, or gemcitabine combined with radiation, respectively. Each chemotherapeutics showed reduced tumor growth through cell cycle arrest, apoptosis or autophagy. Biochemical analyses showed that drug-treated cells showed reduced expressions of phosphorylated ERK, phosphorylated Akt, or phosphorylated RhoA. HIF1A together with HK2 genes was overexpressed in resistant cells. Metabolomics showed differential glycolysis patterns among parental and resistant primary PDAC cells.
Conclusions
The results suggest that the targeting molecules associated with squamous PDAC malignancy discovered in our previous study would provide significant therapeutic advantage. Additionally, hypoxic tumor microenvironment (TME) plays a critical role for chemotherapeutics sensitivity, according to the metabolomics analysis. Importantly, the study implicates the critical role of patient-derived models, especially tumor organoids, for precise evaluation of drug sensitivity, and to validate functional mechanism of drug resistance on individual PDAC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Korea Foundation for the Advancement of Science and Creativity.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09